Brenipatide being investigated for alcohol use disorder, while exploring relapse prevention in recurrent depression and other psychiatric conditions.
Rob Nicholson, PhD
Advertisement
Articles by Rob Nicholson, PhD
Phase 1 brenipatide shows week-long exposure and tolerable GI effects, fueling studies in alcohol and other substance use disorders.
Advertisement
Latest Updated Articles
Brenipatide: Approaching Addiction TreatmentSeptember 19th 2026
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Grants Clearance to Motivista, the First Authorized Treatment for Negative Symptoms of Schizophrenia
2
Muscarinic Treatment for Schizophrenia: A Presynaptic Answer to a Presynaptic Problem
3
Blood-Based Biomarkers for Alzheimer Disease: Accuracy, Limits, and Confounders
4
First Patient Dosed in Phase 2a Trial of GlyphAgo for Generalized Anxiety Disorder and Sleep Disturbance
5